Bugs As Drugs: The Budding Microbiome Modulator Pipeline
INFOGRAPHIC: The sheer number of micro-organisms in the human body and their functions makes the microbiome a ripe target for therapeutic intervention. While still rather early, data show the microbiome modulator pipeline has immense potential across a range of therapeutic areas, not just in gastrointestinal disease.
You may also be interested in...
The US firm has started a rolling US BLA for its infectious disease candidate, SER-109, following positive data from a second late-stage study, a milestone which could draw attention to firms in the microbiome space.
Once deemed an intimidating and risky space, microbiome modulator firms are slowly winning over investors as robust clinical data surface, with one company, Microbiotica, recently hitting an EU financing record.
Microbiome modulators, known mainly for development in infectious and gastrointestinal diseases, could prove an asset in oncology thanks to the work of biotechs.